Abstract
Summary
Irbesartan is a nonpeptide angiotensin II antagonist with antihypertensive activity. Irbesartan selectively and competitively blocks the binding of angiotensin II to the angiotensin I receptor. Angiotensin II stimulates aldosterone synthesis and secretion by adrenal cortex, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle.
LPI (LP Information)' newest research report, the “Irbesartan API Industry Forecast” looks at past sales and reviews total world Irbesartan API sales in 2022, providing a comprehensive analysis by region and market sector of projected Irbesartan API sales for 2023 through 2029. With Irbesartan API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Irbesartan API industry.
This Insight Report provides a comprehensive analysis of the global Irbesartan API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Irbesartan API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Irbesartan API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Irbesartan API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Irbesartan API.
The global Irbesartan API market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Irbesartan API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Irbesartan API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Irbesartan API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Irbesartan API players cover Dr. Reddy’s Laboratories Ltd., Tecoland Corporation, Teva API, Divis Laboratories Ltd., Rundu Pharma, Apeloa Pharmaceutical Co., Ltd., CTX Lifesciences, Unichem Laboratories Limited and Zhejiang Huahai Pharmaceuticals Co., Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Irbesartan API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Purity≥98%
Purity<98%
Segmentation by application
Irbesartan Tablets
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Dr. Reddy’s Laboratories Ltd.
Tecoland Corporation
Teva API
Divis Laboratories Ltd.
Rundu Pharma
Apeloa Pharmaceutical Co., Ltd.
CTX Lifesciences
Unichem Laboratories Limited
Zhejiang Huahai Pharmaceuticals Co., Ltd
Smilax Laboratories Limited
Key Questions Addressed in this Report
What is the 10-year outlook for the global Irbesartan API market?
What factors are driving Irbesartan API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Irbesartan API market opportunities vary by end market size?
How does Irbesartan API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Irbesartan API Industry Forecast” looks at past sales and reviews total world Irbesartan API sales in 2022, providing a comprehensive analysis by region and market sector of projected Irbesartan API sales for 2023 through 2029. With Irbesartan API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Irbesartan API industry.
This Insight Report provides a comprehensive analysis of the global Irbesartan API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Irbesartan API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Irbesartan API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Irbesartan API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Irbesartan API.
The global Irbesartan API market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Irbesartan API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Irbesartan API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Irbesartan API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Irbesartan API players cover Dr. Reddy’s Laboratories Ltd., Tecoland Corporation, Teva API, Divis Laboratories Ltd., Rundu Pharma, Apeloa Pharmaceutical Co., Ltd., CTX Lifesciences, Unichem Laboratories Limited and Zhejiang Huahai Pharmaceuticals Co., Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Irbesartan API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Purity≥98%
Purity<98%
Segmentation by application
Irbesartan Tablets
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Dr. Reddy’s Laboratories Ltd.
Tecoland Corporation
Teva API
Divis Laboratories Ltd.
Rundu Pharma
Apeloa Pharmaceutical Co., Ltd.
CTX Lifesciences
Unichem Laboratories Limited
Zhejiang Huahai Pharmaceuticals Co., Ltd
Smilax Laboratories Limited
Key Questions Addressed in this Report
What is the 10-year outlook for the global Irbesartan API market?
What factors are driving Irbesartan API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Irbesartan API market opportunities vary by end market size?
How does Irbesartan API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Irbesartan API Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Irbesartan API by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Irbesartan API by Country/Region, 2018, 2022 & 2029
2.2 Irbesartan API Segment by Type
2.2.1 Purity≥98%
2.2.2 Purity<98%
2.3 Irbesartan API Sales by Type
2.3.1 Global Irbesartan API Sales Market Share by Type (2018-2023)
2.3.2 Global Irbesartan API Revenue and Market Share by Type (2018-2023)
2.3.3 Global Irbesartan API Sale Price by Type (2018-2023)
2.4 Irbesartan API Segment by Application
2.4.1 Irbesartan Tablets
2.4.2 Others
2.5 Irbesartan API Sales by Application
2.5.1 Global Irbesartan API Sale Market Share by Application (2018-2023)
2.5.2 Global Irbesartan API Revenue and Market Share by Application (2018-2023)
2.5.3 Global Irbesartan API Sale Price by Application (2018-2023)
3 Global Irbesartan API by Company
3.1 Global Irbesartan API Breakdown Data by Company
3.1.1 Global Irbesartan API Annual Sales by Company (2018-2023)
3.1.2 Global Irbesartan API Sales Market Share by Company (2018-2023)
3.2 Global Irbesartan API Annual Revenue by Company (2018-2023)
3.2.1 Global Irbesartan API Revenue by Company (2018-2023)
3.2.2 Global Irbesartan API Revenue Market Share by Company (2018-2023)
3.3 Global Irbesartan API Sale Price by Company
3.4 Key Manufacturers Irbesartan API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Irbesartan API Product Location Distribution
3.4.2 Players Irbesartan API Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Irbesartan API by Geographic Region
4.1 World Historic Irbesartan API Market Size by Geographic Region (2018-2023)
4.1.1 Global Irbesartan API Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Irbesartan API Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Irbesartan API Market Size by Country/Region (2018-2023)
4.2.1 Global Irbesartan API Annual Sales by Country/Region (2018-2023)
4.2.2 Global Irbesartan API Annual Revenue by Country/Region (2018-2023)
4.3 Americas Irbesartan API Sales Growth
4.4 APAC Irbesartan API Sales Growth
4.5 Europe Irbesartan API Sales Growth
4.6 Middle East & Africa Irbesartan API Sales Growth
5 Americas
5.1 Americas Irbesartan API Sales by Country
5.1.1 Americas Irbesartan API Sales by Country (2018-2023)
5.1.2 Americas Irbesartan API Revenue by Country (2018-2023)
5.2 Americas Irbesartan API Sales by Type
5.3 Americas Irbesartan API Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Irbesartan API Sales by Region
6.1.1 APAC Irbesartan API Sales by Region (2018-2023)
6.1.2 APAC Irbesartan API Revenue by Region (2018-2023)
6.2 APAC Irbesartan API Sales by Type
6.3 APAC Irbesartan API Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Irbesartan API by Country
7.1.1 Europe Irbesartan API Sales by Country (2018-2023)
7.1.2 Europe Irbesartan API Revenue by Country (2018-2023)
7.2 Europe Irbesartan API Sales by Type
7.3 Europe Irbesartan API Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Irbesartan API by Country
8.1.1 Middle East & Africa Irbesartan API Sales by Country (2018-2023)
8.1.2 Middle East & Africa Irbesartan API Revenue by Country (2018-2023)
8.2 Middle East & Africa Irbesartan API Sales by Type
8.3 Middle East & Africa Irbesartan API Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Irbesartan API
10.3 Manufacturing Process Analysis of Irbesartan API
10.4 Industry Chain Structure of Irbesartan API
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Irbesartan API Distributors
11.3 Irbesartan API Customer
12 World Forecast Review for Irbesartan API by Geographic Region
12.1 Global Irbesartan API Market Size Forecast by Region
12.1.1 Global Irbesartan API Forecast by Region (2024-2029)
12.1.2 Global Irbesartan API Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Irbesartan API Forecast by Type
12.7 Global Irbesartan API Forecast by Application
13 Key Players Analysis
13.1 Dr. Reddy’s Laboratories Ltd.
13.1.1 Dr. Reddy’s Laboratories Ltd. Company Information
13.1.2 Dr. Reddy’s Laboratories Ltd. Irbesartan API Product Portfolios and Specifications
13.1.3 Dr. Reddy’s Laboratories Ltd. Irbesartan API Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Dr. Reddy’s Laboratories Ltd. Main Business Overview
13.1.5 Dr. Reddy’s Laboratories Ltd. Latest Developments
13.2 Tecoland Corporation
13.2.1 Tecoland Corporation Company Information
13.2.2 Tecoland Corporation Irbesartan API Product Portfolios and Specifications
13.2.3 Tecoland Corporation Irbesartan API Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Tecoland Corporation Main Business Overview
13.2.5 Tecoland Corporation Latest Developments
13.3 Teva API
13.3.1 Teva API Company Information
13.3.2 Teva API Irbesartan API Product Portfolios and Specifications
13.3.3 Teva API Irbesartan API Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Teva API Main Business Overview
13.3.5 Teva API Latest Developments
13.4 Divis Laboratories Ltd.
13.4.1 Divis Laboratories Ltd. Company Information
13.4.2 Divis Laboratories Ltd. Irbesartan API Product Portfolios and Specifications
13.4.3 Divis Laboratories Ltd. Irbesartan API Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Divis Laboratories Ltd. Main Business Overview
13.4.5 Divis Laboratories Ltd. Latest Developments
13.5 Rundu Pharma
13.5.1 Rundu Pharma Company Information
13.5.2 Rundu Pharma Irbesartan API Product Portfolios and Specifications
13.5.3 Rundu Pharma Irbesartan API Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Rundu Pharma Main Business Overview
13.5.5 Rundu Pharma Latest Developments
13.6 Apeloa Pharmaceutical Co., Ltd.
13.6.1 Apeloa Pharmaceutical Co., Ltd. Company Information
13.6.2 Apeloa Pharmaceutical Co., Ltd. Irbesartan API Product Portfolios and Specifications
13.6.3 Apeloa Pharmaceutical Co., Ltd. Irbesartan API Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Apeloa Pharmaceutical Co., Ltd. Main Business Overview
13.6.5 Apeloa Pharmaceutical Co., Ltd. Latest Developments
13.7 CTX Lifesciences
13.7.1 CTX Lifesciences Company Information
13.7.2 CTX Lifesciences Irbesartan API Product Portfolios and Specifications
13.7.3 CTX Lifesciences Irbesartan API Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 CTX Lifesciences Main Business Overview
13.7.5 CTX Lifesciences Latest Developments
13.8 Unichem Laboratories Limited
13.8.1 Unichem Laboratories Limited Company Information
13.8.2 Unichem Laboratories Limited Irbesartan API Product Portfolios and Specifications
13.8.3 Unichem Laboratories Limited Irbesartan API Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Unichem Laboratories Limited Main Business Overview
13.8.5 Unichem Laboratories Limited Latest Developments
13.9 Zhejiang Huahai Pharmaceuticals Co., Ltd
13.9.1 Zhejiang Huahai Pharmaceuticals Co., Ltd Company Information
13.9.2 Zhejiang Huahai Pharmaceuticals Co., Ltd Irbesartan API Product Portfolios and Specifications
13.9.3 Zhejiang Huahai Pharmaceuticals Co., Ltd Irbesartan API Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Zhejiang Huahai Pharmaceuticals Co., Ltd Main Business Overview
13.9.5 Zhejiang Huahai Pharmaceuticals Co., Ltd Latest Developments
13.10 Smilax Laboratories Limited
13.10.1 Smilax Laboratories Limited Company Information
13.10.2 Smilax Laboratories Limited Irbesartan API Product Portfolios and Specifications
13.10.3 Smilax Laboratories Limited Irbesartan API Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Smilax Laboratories Limited Main Business Overview
13.10.5 Smilax Laboratories Limited Latest Developments
14 Research Findings and Conclusion